Pharma in Indonesia: Competing for Higher Margins

In this article (5)
IPMG members – including Novartis, Merck, Bayer, Boehringer Ingelheim, and Pfizer – have invested more than USD $1 billion in Indonesia’s pharmaceutical industry over the past few years, particularity for the construction of factories and clinical research (source: AmCham Indonesia).
An example is Bayer, which recently invested 8.1 million euros in the expansion of its factory in Cimanggis (West Java). This factory produces multivitamins and medicines, about 75% of which is exported to 26 countries.
Concurrently, Indonesia’s largest pharmaceutical company, Kalbe Farma, is shifting from being a maker of generic drugs to a high-tech pharma developer. Besides producing cancer drugs, Kalbe has been investing in R&D on stem cell therapies. Significantly, a lack of generic substitutes in these fields in Indonesia implies no government-set price ceilings, and therefore these products offer higher margins.
In fact, there are more than 200 drugmakers in Indonesia, most of which produce only low-margin generics. While they control 95% of the market by volume, they have a combined 75% share in value terms. Therefore the few multinationals operating in the country have been able to make more profits because of their focus on high-value products.
Such activities are taking place while Indonesian President Joko Widodo is pushing its universal health care program to cover the country’s projected population of 270 million by 2019, a leap from the 170 million currently covered. This year for the first time, government expenditures on health care reached the legally mandated 5% of the state budget. Health care spending is expected to grow 12% every year through 2020.
To join the discussion on all developments in this industry sign up for CPhI South East Asia and its LinkedIn group. CPhI is the must-attend pharma event in Indonesia comprising of a trade show and state of the art conference where the regional industry meets to leverage connections, knowledge and insight to spur business. Launched 6 years ago, the next edition takes place during 22-24 March 2017 at JIExpo in Jakarta. Workshops and exhibitors’ presentations will add into the mix, and will complement the 3 days together with a business matchmaking platform.
Questions & Answers
Q.Which pharmaceutical companies have invested in Indonesia and how much have they spent in total?
Which pharmaceutical companies have invested in Indonesia and how much have they spent in total?
Members of IPMG, including Novartis, Merck, Bayer, Boehringer Ingelheim, and Pfizer, have invested over USD $1 billion. This investment primarily went into constructing factories and conducting clinical research within Indonesia's pharmaceutical industry.
Q.Why do multinational pharmaceutical companies in Indonesia achieve higher profit margins compared to most local drugmakers?
Why do multinational pharmaceutical companies in Indonesia achieve higher profit margins compared to most local drugmakers?
Multinationals focus on high-value products like cancer drugs and stem cell therapies, where a lack of generic substitutes means no government-set price ceilings. Most local drugmakers produce low-margin generics, controlling volume but less value.
Q.What is the Indonesian government's target for universal health care coverage and by when does it aim to achieve this?
What is the Indonesian government's target for universal health care coverage and by when does it aim to achieve this?
President Joko Widodo is pushing to cover a projected population of 270 million by 2019. This is a significant increase from the 170 million people currently covered by the universal health care program.
Q.What are the future financial expectations for health care spending in Indonesia?
What are the future financial expectations for health care spending in Indonesia?
Government expenditure on health care reached the legally mandated 5% of the state budget this year for the first time. Spending is predicted to grow by 12% annually through to 2020.
Reader pulse
Is Indonesia's pharma market ready for this high-tech shift?
19,743 votes so far